Beta-Peptides and Gamma-Peptides Explained

Peptidomimetics and Modified Backbones

1 Extra Carbon

Adding a single carbon atom to the peptide backbone creates beta-peptides that are completely invisible to every protease tested, while still folding into predictable helical structures.

Seebach et al., Chemistry & Biodiversity, 2004

Seebach et al., Chemistry & Biodiversity, 2004

View as image

Natural peptides have a critical weakness: proteases destroy them within minutes in the body. Every amino acid in a natural (alpha) peptide has one carbon atom between its amino and carboxyl groups. Beta-peptides add a single extra carbon to that backbone. Gamma-peptides add two. These small structural changes produce molecules that retain the ability to fold into defined three-dimensional shapes while becoming completely invisible to the enzymes that degrade natural peptides.

This resistance to degradation is not partial. Seebach et al. reported in their landmark 2004 review that beta- and gamma-peptides showed complete stability against proteolytic enzymes of all types tested, including mammalian, microbial, and yeast proteases, and demonstrated extraordinary metabolic stability in vivo in mice and rats.^[1] As peptoid cousins achieve protease resistance through a different backbone modification, beta- and gamma-peptides represent an alternative route to the same goal.

The Backbone That Changes Everything

In a standard alpha-peptide, each amino acid residue has the structure: amino group, one carbon (the alpha-carbon bearing the side chain), then carboxyl group. The backbone repeats this pattern. A beta-amino acid inserts an additional methylene group (CH2) between the amino and carboxyl groups, creating a backbone with two carbon atoms per residue instead of one. A gamma-amino acid adds yet another, for three carbons per residue.^[1]

This structural change has three consequences. First, the additional backbone carbons create more rotational freedom, which paradoxically leads to predictable folding when the right residues are chosen. Second, the extended backbone generates different hydrogen-bonding patterns, producing helices with different geometries than the alpha-helix found in natural proteins. Third, and most practically, the altered backbone is not recognized by any known protease. Since proteases evolved to cleave the specific bond geometry of alpha-amino acids, the unfamiliar bond geometry of beta- and gamma-amino acids renders these molecules invisible to enzymatic degradation.

The extra carbon also introduces new possibilities for side-chain placement. Beta-amino acids can bear substituents on the carbon adjacent to the amino group (beta2-amino acids), on the carbon adjacent to the carboxyl group (beta3-amino acids), or on both. Each substitution pattern influences which secondary structures the resulting peptide adopts, providing a design toolkit unavailable in natural peptide chemistry.

Three Helices No Natural Peptide Can Form

The most striking feature of beta-peptides is their structural diversity. Where alpha-peptides form essentially one helix (the alpha-helix, stabilized by i to i+4 hydrogen bonds), beta-peptides adopt at least three distinct helical conformations.^[1]

The 14-helix is the most extensively studied. Named for the 14-atom rings formed by its hydrogen bonds (C=O of residue i to N-H of residue i+2), it has approximately three residues per turn and a left-handed twist. Unlike the alpha-helix, which requires roughly 15 residues to form a stable structure in solution, the 14-helix is observable in beta-peptides as short as four residues. This early-onset folding makes beta-peptides practical building blocks even at short lengths.

The 12-helix features tighter hydrogen-bond rings (12 atoms, i to i+3 pattern), producing a helix with a different pitch and diameter. The 10/12-helix alternates between 10-atom and 12-atom hydrogen-bond rings, creating a mixed pattern found in beta-peptides composed of alternating beta2- and beta3-amino acids.

Each helix type positions side chains differently in three-dimensional space. This geometric control is what enables the rational design of beta-peptides for specific biological targets. The 14-helix, for instance, arranges residues along three faces of the helix, making it straightforward to design amphiphilic structures where hydrophobic and hydrophilic residues are segregated onto opposite sides. This is the design principle underlying antimicrobial beta-peptides.

The Beta/Gamma 13-Helix: Mimicking Nature Without Alpha-Amino Acids

When beta- and gamma-amino acid residues alternate in a 1:1 pattern, the resulting oligomer adopts a distinctive helix stabilized by i to i+3 C=O to N-H hydrogen bonds forming 13-atom rings. Guo and Gellman reported the first high-resolution structural characterization of this beta/gamma-peptide 13-helix in 2010, providing both X-ray crystallographic and 2D NMR data.^[2]

The 13-helix is particularly interesting because its hydrogen-bonding pattern is analogous to that of the natural alpha-helix (also i to i+3, but with 13-atom rather than 13-atom rings in the alpha case), yet it contains no alpha-amino acid residues at all. This means it can potentially mimic the surface features of natural alpha-helical protein segments while retaining full protease resistance. The key to achieving well-defined folding was using conformationally preorganized (cyclic) beta- and gamma-residues rather than flexible acyclic ones, which tended to adopt different helical forms in earlier studies.^[2]

This alpha-helix mimicry has direct therapeutic relevance. Many protein-protein interactions are mediated by alpha-helical segments, and designing molecules that can present the same arrangement of functional groups on a protease-resistant backbone is a central challenge in de novo peptide design.

Antimicrobial Beta-Peptides: Matching Natural Defenses

One of the earliest and most compelling applications of beta-peptides has been as antimicrobial agents. Raguse et al. from the Gellman laboratory published a detailed structure-activity study in 2002, creating two series of cationic, amphiphilic beta-peptides designed to adopt the 14-helical conformation.^[3]

The study probed a fundamental question: does the stability of the helical fold determine antimicrobial potency? Using mixtures of rigid trans-2-aminocyclohexanecarboxylic acid (ACHC) residues and flexible acyclic residues, they created beta-peptides spanning a broad range of 14-helix stability in aqueous solution. The results were surprising. Helical stability had minimal effect on antibiotic activity against four bacterial species, including E. coli, S. aureus, B. subtilis, and E. faecalis. Several 9-residue beta-peptides showed antimicrobial activity comparable to a synthetic derivative of the natural antimicrobial peptide magainin.^[3]

This finding was important for two reasons. First, it demonstrated that short beta-peptides could match the antimicrobial activity of natural alpha-helical peptides. Second, the weak correlation between helix stability and antimicrobial potency suggested that beta-peptides might function through mechanisms that do not require a pre-folded structure in solution, possibly adopting their amphiphilic conformation upon contact with bacterial membranes.

The hemolytic activity (toxicity to red blood cells) was low for the 9-residue series and increased only slightly with increasing helical propensity. This suggested a practical therapeutic window: beta-peptides could kill bacteria at concentrations below those that damage mammalian cells.

Disrupting "Undruggable" Protein-Protein Interactions

Beyond antimicrobial applications, beta-peptides have opened approaches to a target class long considered undruggable: protein-protein interactions (PPIs). Kritzer and Schepartz described in 2005 the development of 14-helical beta-peptide scaffolds designed to bind protein surfaces and inhibit PPIs with affinities and specificities comparable to those of natural or miniature proteins.^[4]

The challenge was creating beta-peptide scaffolds that maintained well-defined 14-helical structure in water while tolerating the diverse sequence variation needed to generate high-affinity protein surface ligands. Their approach used rigid cyclic residues to enforce the helical backbone while incorporating acyclic residues with varied side chains to create the binding surface. This strategy produced beta-peptides that could disrupt therapeutically relevant PPIs, opening a path toward protease-resistant PPI inhibitors.

This work connects to the broader peptidomimetics field, where multiple strategies, including stapled peptides, D-amino acid peptides, and cyclic peptides, are all pursuing the same goal: creating peptide-like molecules that survive long enough in the body to reach their targets.

The Current Landscape: Foldamers in Drug Discovery

A 2024 review in Expert Opinion on Drug Discovery assessed the state of beta-peptide, gamma-peptide, and other foldamer architectures for pharmaceutical applications.^[5] The field has expanded beyond the alpha, beta, and gamma backbone modifications to include urea-type foldamers, sulfonic gamma-amino acid foldamers, aromatic foldamers, and hybrid architectures combining multiple backbone types.

The review highlighted three application areas where foldamers show the strongest evidence. First, antimicrobial foldamers have demonstrated activity against drug-resistant bacteria, with their protease resistance giving them an advantage over natural antimicrobial peptides that degrade too rapidly for therapeutic use. Second, foldamers function as drug delivery systems, with some penetrating cell membranes 3 to 30 times more effectively than the original peptides they were derived from.^[5] Third, foldamers serve as protein-protein interaction inhibitors targeting cancer-associated pathways with a combination of specificity, versatility, and metabolic stability that natural peptides cannot achieve.

A 2015 overview by Mandity and Fulop in Expert Opinion on Drug Discovery provided the framework that the 2024 review builds upon, cataloguing the key properties that make foldamers attractive drug candidates: stable and designable secondary structure, a larger molecular surface compared to small-molecule drugs, controlled side-chain orientation, and resistance to proteolytic degradation leading to potentially increased oral bioavailability and longer serum half-life relative to natural alpha-peptides.^[6]

What Stands Between Foldamers and the Clinic

Despite three decades of research, no beta-peptide or gamma-peptide drug has reached clinical approval. The gap between laboratory promise and clinical reality reflects several persistent challenges.

Synthesis cost remains high. Beta- and gamma-amino acids with the correct stereochemistry are expensive to produce, and the specialized coupling conditions required for foldamer synthesis add to manufacturing complexity. Natural alpha-amino acids benefit from mature, optimized industrial production. Foldamer synthesis does not yet have equivalent economies of scale.

Pharmacokinetic characterization is incomplete. While protease resistance is well-established, the absorption, distribution, metabolism, and excretion (ADME) profiles of beta- and gamma-peptides in humans remain largely unknown. Seebach's 2004 review noted organ-specific distribution after intravenous administration in rats and transport through rodent intestines, but systematic human pharmacokinetic data are lacking.^[1]

Target validation is still evolving. For antimicrobial applications, beta-peptides must demonstrate advantages over existing antibiotics and natural antimicrobial peptides to justify their higher cost. For PPI inhibition, the competition includes stapled peptides, macrocyclic peptides, and increasingly sophisticated small molecules. Each approach has trade-offs, and the optimal strategy depends on the specific target.

The field also faces a selectivity question. Beta- and gamma-peptides that are designed for membrane disruption (the antimicrobial mechanism) must show sufficient selectivity for bacterial over mammalian membranes. While the Gellman group's 2002 data showed a therapeutic window for their 9-residue beta-peptides, achieving adequate selectivity at longer chain lengths or different compositions is not guaranteed.

Biological degradation presents an unusual challenge from the opposite direction. Because beta- and gamma-peptides resist proteolysis so completely, their environmental persistence raises questions about clearance from the body and potential accumulation. Seebach noted that even biological degradation by microbial colonies found in sewage-treatment plants or in soil was very slow.^[1] A drug that the body cannot break down must be designed with clearance in mind from the outset, likely relying on renal excretion rather than metabolic processing.

Hybrid approaches may offer the most practical near-term path. Alpha/beta-peptides, which intersperse natural alpha-amino acids with beta-amino acid residues at strategic positions, retain enough natural character for some biological recognition while gaining partial protease resistance. These hybrids represent a compromise: not as protease-resistant as pure beta-peptides, but easier to synthesize and closer to the natural peptide structures that biological systems already recognize. The cyclization approach offers a complementary strategy, combining backbone modification with conformational constraint to achieve both stability and target affinity.

The Bottom Line

Beta-peptides and gamma-peptides represent a fundamentally different approach to peptide-based drug design: modifying the backbone itself rather than the side chains. The addition of one or two extra carbon atoms per residue creates molecules that fold into predictable helical structures, resist all known proteases, and can be designed to target bacterial membranes or protein-protein interaction surfaces. While no foldamer drug has reached clinical approval, the combination of structural predictability and metabolic stability positions these molecules as a bridge between traditional peptide drugs (effective but rapidly degraded) and small-molecule drugs (stable but limited in their ability to target large protein surfaces).

Frequently Asked Questions

What is the difference between alpha-peptides, beta-peptides, and gamma-peptides?

The difference lies in backbone length. Alpha-peptides (natural peptides) have one carbon between the amino and carboxyl groups in each residue. Beta-peptides have two carbons, and gamma-peptides have three. These extra carbons change the molecule's folding behavior and make it invisible to proteases, which evolved to cleave only the alpha-peptide bond geometry (Seebach et al., Chemistry and Biodiversity, 2004).

Why are beta-peptides resistant to proteases?

Proteases are enzymes that recognize and cleave the specific bond geometry of alpha-amino acids. Beta-amino acids have an additional carbon in their backbone, creating a bond geometry that does not fit the active site of any known protease. Tests with mammalian, microbial, and yeast proteases showed complete stability. In vivo studies in mice and rats confirmed extraordinary metabolic stability even with functionalized side chains (Seebach et al., 2004).

Can beta-peptides kill bacteria like natural antimicrobial peptides?

Yes. Short (9-residue) amphiphilic beta-peptides designed to adopt the 14-helical conformation showed antimicrobial activity comparable to a synthetic derivative of magainin, a well-known natural antimicrobial peptide, against E. coli, S. aureus, B. subtilis, and E. faecalis. These beta-peptides were also less hemolytic (less toxic to red blood cells) than the magainin derivative (Raguse et al., JACS, 2002).

What are foldamers and how do they relate to beta-peptides?

Foldamers are artificial molecules that fold into predictable three-dimensional structures, similar to how proteins fold into defined shapes. Beta-peptides and gamma-peptides are types of peptide foldamers. Other foldamer categories include peptoids, urea-type foldamers, and aromatic foldamers. All share key properties: stable secondary structure, controlled side-chain orientation, and resistance to enzymatic degradation (Mandity and Fulop, 2015).

Are beta-peptide drugs available yet?

No beta-peptide or gamma-peptide drug has reached clinical approval. The main barriers are high synthesis cost, incomplete pharmacokinetic data in humans, and competition from other drug modalities. However, foldamers show strong preclinical evidence as antimicrobial agents, protein-protein interaction inhibitors, and drug delivery systems (Dongrui et al., Expert Opinion on Drug Discovery, 2024).

How do beta/gamma-peptides mimic natural protein helices?

Alternating beta- and gamma-amino acid residues in a 1:1 pattern creates the 13-helix, which has a hydrogen-bonding pattern analogous to the natural alpha-helix but contains no alpha-amino acids. Using conformationally preorganized (cyclic) residues enforces this helical folding. The result is a protease-resistant molecule that can present the same arrangement of functional groups as a natural helical protein segment (Guo and Gellman, JACS, 2010).